Becton, Dickinson and Company Forecasted to Post Q2 2023 Earnings of $2.81 Per Share (NYSE:BDX)

Becton, Dickinson and Company (NYSE:BDXGet Rating) – Analysts at KeyCorp issued their Q2 2023 earnings per share estimates for Becton, Dickinson and in a research note issued to investors on Thursday, November 10th. KeyCorp analyst M. Mishan forecasts that the medical instruments supplier will post earnings per share of $2.81 for the quarter. The consensus estimate for Becton, Dickinson and’s current full-year earnings is $12.02 per share. KeyCorp also issued estimates for Becton, Dickinson and’s Q3 2023 earnings at $3.14 EPS, Q4 2023 earnings at $3.38 EPS, FY2023 earnings at $11.90 EPS and FY2024 earnings at $13.41 EPS.

Becton, Dickinson and (NYSE:BDXGet Rating) last announced its quarterly earnings data on Thursday, November 10th. The medical instruments supplier reported $2.75 EPS for the quarter, beating the consensus estimate of $2.74 by $0.01. The firm had revenue of $4.76 billion during the quarter, compared to analyst estimates of $4.72 billion. Becton, Dickinson and had a net margin of 9.16% and a return on equity of 14.56%. Becton, Dickinson and’s revenue was down 6.6% on a year-over-year basis. During the same period last year, the firm posted $2.15 EPS.

Several other equities analysts also recently issued reports on BDX. The Goldman Sachs Group upped their target price on Becton, Dickinson and from $278.00 to $319.00 and gave the company a “buy” rating in a research report on Tuesday, August 16th. Stifel Nicolaus cut their price objective on Becton, Dickinson and from $290.00 to $280.00 in a report on Monday, July 18th. Morgan Stanley lifted their target price on Becton, Dickinson and from $272.00 to $275.00 and gave the stock an “overweight” rating in a report on Tuesday, October 11th. Piper Sandler cut their price target on shares of Becton, Dickinson and from $255.00 to $245.00 and set a “neutral” rating on the stock in a report on Thursday. Finally, StockNews.com cut shares of Becton, Dickinson and from a “buy” rating to a “hold” rating in a research note on Friday. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $275.75.

Becton, Dickinson and Trading Down 0.7 %

NYSE BDX opened at $227.67 on Monday. The stock has a market cap of $64.93 billion, a P/E ratio of 38.72, a P/E/G ratio of 2.45 and a beta of 0.61. The company has a current ratio of 1.35, a quick ratio of 0.90 and a debt-to-equity ratio of 0.58. Becton, Dickinson and has a 12-month low of $215.90 and a 12-month high of $280.62. The company has a fifty day simple moving average of $234.58 and a two-hundred day simple moving average of $244.44.

Becton, Dickinson and Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 30th. Stockholders of record on Friday, December 9th will be issued a dividend of $0.91 per share. This represents a $3.64 annualized dividend and a dividend yield of 1.60%. This is a positive change from Becton, Dickinson and’s previous quarterly dividend of $0.87. The ex-dividend date is Thursday, December 8th. Becton, Dickinson and’s payout ratio is 59.18%.

Hedge Funds Weigh In On Becton, Dickinson and

Large investors have recently made changes to their positions in the company. Dorsey & Whitney Trust CO LLC raised its position in shares of Becton, Dickinson and by 1.6% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 2,535 shares of the medical instruments supplier’s stock worth $675,000 after acquiring an additional 41 shares during the period. Tranquilli Financial Advisor LLC raised its holdings in Becton, Dickinson and by 4.8% in the 2nd quarter. Tranquilli Financial Advisor LLC now owns 912 shares of the medical instruments supplier’s stock worth $225,000 after purchasing an additional 42 shares during the period. Capital Asset Advisory Services LLC boosted its position in Becton, Dickinson and by 3.1% during the second quarter. Capital Asset Advisory Services LLC now owns 1,433 shares of the medical instruments supplier’s stock worth $353,000 after purchasing an additional 43 shares in the last quarter. Armor Investment Advisors LLC grew its holdings in Becton, Dickinson and by 0.5% in the first quarter. Armor Investment Advisors LLC now owns 8,319 shares of the medical instruments supplier’s stock valued at $2,213,000 after purchasing an additional 44 shares during the period. Finally, McIlrath & Eck LLC raised its stake in shares of Becton, Dickinson and by 44.9% during the 1st quarter. McIlrath & Eck LLC now owns 142 shares of the medical instruments supplier’s stock worth $38,000 after buying an additional 44 shares during the period. 86.74% of the stock is currently owned by institutional investors and hedge funds.

Becton, Dickinson and Company Profile

(Get Rating)

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.

Featured Stories

Earnings History and Estimates for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.